These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9462441)

  • 1. MICs of rifampicin and chloramphenicol for mucoid Pseudomonas aeruginosa strains are lower when human lactoferrin is present.
    Fowler CE; Soothill JS; Oakes L
    J Antimicrob Chemother; 1997 Dec; 40(6):877-9. PubMed ID: 9462441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains.
    Alkawash M; Head M; Alshami I; Soothill JS
    J Antimicrob Chemother; 1999 Sep; 44(3):385-7. PubMed ID: 10511407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Micronaut Merlin automated broth microtiter system with the standard agar dilution method for antimicrobial susceptibility testing of mucoid and nonmucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2004 Oct; 23(10):765-71. PubMed ID: 15605183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic tolerance induced by lactoferrin in clinical Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Andrés MT; Viejo-Diaz M; Pérez F; Fierro JF
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1613-6. PubMed ID: 15793153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa.
    Ghani M; Soothill JS
    Can J Microbiol; 1997 Nov; 43(11):999-1004. PubMed ID: 9436304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifampicin potentiation of aminoglycoside activity against cystic fibrosis isolates of Pseudomonas aeruginosa.
    Mikalauskas A; Parkins MD; Poole K
    J Antimicrob Chemother; 2017 Dec; 72(12):3349-3352. PubMed ID: 28961705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucoid and pigmentation characters can be suppressed by non-anti-Pseudomonas aeruginosa antibiotics in cystic fibrosis: a report of promising preliminary results.
    Lapointe JR; Bourget C; Lafleur L; Lagacé J; Montplaisir S
    Drugs Exp Clin Res; 1988; 14(8):501-10. PubMed ID: 3150349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
    Idowu T; Arthur G; Zhanel GG; Schweizer F
    Eur J Med Chem; 2019 Jul; 174():16-32. PubMed ID: 31022550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
    King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the sensibility "in vitro" to antibiotics of 77 strains of "Pseudomonas aeruginosa" (author's transl)].
    Padovani F; Pilotti C
    Ann Sclavo; 1976; 18(5):749-54. PubMed ID: 829305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T; Petrova G; Mitov I
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Isolation rate of Pseudomonas aeruginosa from clinical materials and its susceptibility to antibiotics].
    Oguri T; Kosakai N
    Jpn J Antibiot; 1971 Jun; 24(3):121-5. PubMed ID: 4327335
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro susceptibilities of mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients against azthreonam, netilmicin and piperacillin.
    Flournoy DJ; Cox FR
    Methods Find Exp Clin Pharmacol; 1984 Sep; 6(9):487-9. PubMed ID: 6439964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative effect of roxithromycin and rifampicin on mucoid cultures from directly plated sputum of cystic fibrosis patients chronically colonized with Pseudomonas aeruginosa.
    Dupont MJ; Lapointe JR
    Drugs Exp Clin Res; 1990; 16(12):597-605. PubMed ID: 2130001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of medium temperature and pH on the sensitivity of pathogenic pseudomonads to chemotherapeutic agents].
    Iliukhin VI; Batmanov VP
    Antibiot Khimioter; 1997; 42(4):21-3. PubMed ID: 9182502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of hypothiocyanite and lactoferrin (ALX-009) against respiratory cystic fibrosis pathogens in sputum.
    Tunney MM; Payne JE; McGrath SJ; Einarsson GG; Ingram RJ; Gilpin DF; Juarez-Perez V; Elborn JS
    J Antimicrob Chemother; 2018 Dec; 73(12):3391-3397. PubMed ID: 30219825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of lactoferrin on biofilm formation in clinical isolates of Pseudomonas aeruginosa.
    Kamiya H; Ehara T; Matsumoto T
    J Infect Chemother; 2012 Feb; 18(1):47-52. PubMed ID: 21866304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa.
    Zuravleff JJ; Yu VL; Yee RB
    J Lab Clin Med; 1983 Jun; 101(6):896-902. PubMed ID: 6406628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.